CBT108

CBT108 is an investigational recombinant humanized monoclonal antibody designed to target the Programmed Cell Death Protein 1 (PD-1) receptor. Developed by Shanghai Huali Bio-Pharmaceutical, a subsidiary of Huadong Medicine, CBT108 functions as an immune checkpoint inhibitor by blocking the interaction between PD-1 on T cells and its ligands, PD-L1 and PD-L2, which are frequently overexpressed on tumor cells. This blockade prevents the suppression of T-cell activity, thereby restoring and enhancing the immune system's ability to recognize and eliminate cancer cells. CBT108 is currently being evaluated in Phase I clinical trials for the treatment of advanced solid tumors, where it is being assessed for safety, tolerability, and preliminary anti-tumor efficacy.